leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 21:09:31 - browse：68227

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Cassava reveals details — and problems — with Alzheimer's study

WSS

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

What is STAT's opinion section for?

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Medtronic CEO on promising devices for diabetes, hypertension

CVS, Rite Aid closures threaten to worsen pharmacy deserts

entertainment

leisure time

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Today's health inequities arise from racist U.S. history, say experts

Walensky prepares to leave CDC — and Congress — behind

Senate panel to vote on hospitals, PBMs, prisoner care

Apple is now the first public company to be valued at $3 trillion

Healthy food access boosts outcomes in two studies

As demand for Covid shots wanes, Moderna seeks its next success

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Psychedelics group wrestles with new pharma identity

Testing for cancer recurrence creates a new limbo for patients

Wikipedia

Medical school prerequisites are outdated

Emergency medicine has repudiated 'excited delirium.' Now what?

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Readout Newsletter: XBI biotech index, Akero Therapeutics

Publishing genetic code of viruses could cause disaster

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

knowledge

leisure time

hotspot

focus